Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder - PubMed (original) (raw)

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder

C Wright et al. Br J Cancer. 1991 Jun.

Free PMC article

Abstract

Expression of the p53, the epidermal growth factor receptor (EGFr; c-erbB-1) and c-erbB-2 proteins was studied in 82 patients with primary transitional cell carcinoma of the bladder using an immuno-histochemical method. Strong or moderate staining was found in 18% of tumours for p53 with weaker staining in a further 36% giving a total of 54% of tumours stained for p53. Strong staining was found in 15% of tumours for c-erbB-2 and in 31% for the EGFr. Tumours invading the bladder muscle were significantly more likely to be strongly stained positively for p53 and/or EGFr compared with superficial tumours: only 15% of invasive tumours were stained negatively for both p53 and EGFr. No statistical association was found between p53 and EGFr expression. Weakly positive associations were found between the expression of c-erbB-2 and p53 and between muscle invasive tumours and increased expression of c-erbB-2. Alterations in the expression of p53, c-erbB-1 and c-erbB-2 were found frequently in human transitional cell carcinoma of the urinary bladder and may be of clinical use in defining patient sub-groups of differing prognosis.

PubMed Disclaimer

Cited by

P53 accumulation in precursor lesions and early stages of bladder cancer.
Schmitz-Dräger BJ, van Roeyen CR, Grimm MO, Gerharz CD, Decken K, Schulz WA, Bültel H, Makri D, Ebert T, Ackermann R. Schmitz-Dräger BJ, et al. World J Urol. 1994;12(2):79-83. doi: 10.1007/BF00184241. World J Urol. 1994. PMID: 8087143
Chemical carcinogenesis of the urinary bladder--a status report.
Jones RF, Debiec-Rychter M, Wang CY. Jones RF, et al. J Cancer Res Clin Oncol. 1992;118(6):411-9. doi: 10.1007/BF01629423. J Cancer Res Clin Oncol. 1992. PMID: 1618888
p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions.
Kamel D, Soini Y, Nuorva K, Khalifa A, Mangoud A, Vähäkangas K, Pääkkö P. Kamel D, et al. Virchows Arch. 1994;424(4):349-55. doi: 10.1007/BF00190555. Virchows Arch. 1994. PMID: 7911381
Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.
Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ, et al. Sauter G, et al. Am J Pathol. 1994 Apr;144(4):756-66. Am J Pathol. 1994. PMID: 8160775 Free PMC article.

References

1. Br J Cancer. 1990 Nov;62(5):764-5 - PubMed
1. Nature. 1979 Mar 15;278(5701):261-3 - PubMed
1. Science. 1989 May 12;244(4905):707-12 - PubMed
1. Cancer Res. 1989 Apr 15;49(8):2087-90 - PubMed
1. J Virol. 1989 Feb;63(2):739-46 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder - PubMed (original) (raw)